Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600X Vemurafenib cholangiocarcinoma sensitive detail...
Unknown unknown Zebularine cholangiocarcinoma not applicable detail...
FGFR2 fusion Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 mutant Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - ZMYM4 FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 E565A FGFR2 K659M Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - OPTN FGFR2 N549H FGFR2 V564F FGFR2 E565A FGFR2 L617V FGFR2 K641R Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - BICC1 FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 fusion FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
Unknown unknown Cabozantinib cholangiocarcinoma not applicable detail...
Unknown unknown OPB-111077 cholangiocarcinoma not applicable detail...
ERBB2 over exp HER2 CAR-T cells cholangiocarcinoma predicted - sensitive detail...
IDH1 mutant Ivosidenib cholangiocarcinoma sensitive detail...
FGFR2 fusion Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 amp FGFR2 rearrange Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Pemigatinib cholangiocarcinoma sensitive detail...
Unknown unknown Silmitasertib cholangiocarcinoma not applicable detail...
Unknown unknown Cisplatin + Gemcitabine + Silmitasertib cholangiocarcinoma not applicable detail...
FGFR2 - DDX21 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
FGFR2 - KIAA1217 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
FGFR2 - ROCK1 Debio 1347 cholangiocarcinoma predicted - sensitive detail...
Unknown unknown Sabatolimab cholangiocarcinoma not applicable detail...
FGFR2 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR3 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - PPHLN1 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Infigratinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A FGFR2 L617M Infigratinib cholangiocarcinoma predicted - resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Infigratinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Infigratinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 AZD4547 cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Erdafitinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Futibatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A AZD4547 cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Erdafitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Futibatinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 Dovitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 E565A Dovitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M AZD4547 cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Erdafitinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Futibatinib cholangiocarcinoma resistant detail...
FGFR2 - SHTN1 FGFR2 L617M Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - SHTN1 FGFR2 E565A Ponatinib cholangiocarcinoma sensitive detail...
FGFR2 - TTC28 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 fusion Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 - CLIP1 Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CLIP1 FGFR2 N549H Pemigatinib cholangiocarcinoma predicted - resistant detail...
BRAF V600E Vemurafenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132C Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132S Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132L Ivosidenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132G Ivosidenib cholangiocarcinoma predicted - sensitive detail...
FGFR3 amp Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 amp Infigratinib cholangiocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01825603 Phase I ADH-1 + Cisplatin + Gemcitabine ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Completed
NCT01888302 Phase I Cisplatin + Gemcitabine + Sirolimus Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery Completed
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02053376 Phase II Regorafenib A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed
NCT02128282 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Silmitasertib Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Recruiting
NCT02150967 Phase II Infigratinib A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02232633 Phase II BBI503 A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Active, not recruiting
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02452970 Phase II RRx-001 Cisplatin + Gemcitabine RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Terminated
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated
NCT02508467 Phase I Fisogatinib A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Active, not recruiting
NCT02520141 Phase II Ramucirumab Ramucirumab for Advanced Pre-treated Biliary Cancers Recruiting
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Recruiting
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated
NCT02711553 Phase II Ramucirumab Merestinib Cisplatin + Gemcitabine A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02856568 Phase I Cisplatin + Gemcitabine + Ricolinostat Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn
NCT02924376 Phase II Pemigatinib Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy Active, not recruiting
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT02982720 Phase II Peginterferon alfa-2b + Pembrolizumab Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Terminated
NCT02989857 Phase III Ivosidenib Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Active, not recruiting
NCT03093870 Phase II Capecitabine + Varlitinib Capecitabine Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Active, not recruiting
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Active, not recruiting
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Recruiting
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated
NCT03201458 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Recruiting
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Recruiting
NCT03230318 Phase II Derazantinib Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) Recruiting
NCT03250273 Phase II Entinostat + Nivolumab A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Recruiting
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting
NCT03267940 Phase I Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Terminated
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03368963 Phase Ib/II MM-398 + trifluridine/tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting
NCT03377179 Phase II ABC294640 A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03656536 Phase III Pemigatinib Cisplatin + Gemcitabine A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting
NCT03773302 Phase III Cisplatin + Gemcitabine Infigratinib Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting
NCT03878095 Phase II AZD6738 + Olaparib Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Recruiting
NCT03943004 Phase I DFP-14927 Trial of DFP-14927 in Advanced Solid Tumors Recruiting
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Recruiting
NCT04003896 Phase II Abemaciclib A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy Not yet recruiting
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Recruiting
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Recruiting
NCT04068194 Phase Ib/II Avelumab Avelumab + MSC2490484A Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting
NCT04088188 Phase I Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Not yet recruiting
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Recruiting
NCT04233567 Phase II Infigratinib Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Recruiting
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Recruiting
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Recruiting
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting